| Autor: |
Alshehri AS; Section of Biochemical Genetics and Toxicology, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh 11525, Saudi Arabia., Peer-Zada AA; Section of Biochemical Genetics and Toxicology, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh 11525, Saudi Arabia., Algadhi AA; Section of Biochemical Genetics and Toxicology, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh 11525, Saudi Arabia., Aldehaimi A; Section of Biochemical Genetics and Toxicology, Pathology and Clinical Laboratory Medicine Administration, King Fahad Medical City, Riyadh 11525, Saudi Arabia., Saleh MA; Section of Medical Genetics, Department of Pediatrics, King Fahad Medical City, Riyadh 11525, Saudi Arabia., Mushiba AM; Section of Medical Genetics, Department of Pediatrics, King Fahad Medical City, Riyadh 11525, Saudi Arabia., Faqeih EA; Section of Medical Genetics, Department of Pediatrics, King Fahad Medical City, Riyadh 11525, Saudi Arabia., AlAsmari AM; Section of Medical Genetics, Department of Pediatrics, King Fahad Medical City, Riyadh 11525, Saudi Arabia. |
| Abstrakt: |
Inborn errors of metabolism (IEM) and endocrine disorders are common genetic conditions in the Saudi population with the incidence rate often underestimated. Newborn screening (NBS) using various disease panels provides the first line in the early detection and intervention among infants with a high risk of IEM. Here we aim to assess the incidence of screening disorders and provide an overview of the NBS program at the Ministry of Health Tertiary Care King Fahad Medical City. Dried blood spots (DBS) from 40,965 newborn infants collected on the second day after birth were analyzed for 20 disorders. The total number of positive screen ("repeat") samples over 10 years was about 1% ( n = 382/40,965). The true positive result rate was 15.3% ( n = 46/301) with the recall rates of individual disorders ranging from 0.26% (95% CI, 0.17-0.69) to 2.6% (95% CI, 2.19-3.05). The false positive result rate was 84.7% ( n = 255/301) with biotinidase activity found to be the most common cause of the second sample repeat. The overall incidence of the screened diseases was 1:891 (95% CI, 11.61-12.47). CH and CAH are the most prevalent among endocrine disorders with an incidence of 1:4097 (95% CI, 2.19-3.05), and PA and ASA among the IEM with an incidence of 1:10,241 (95% CI, 0.09-0.95). In summary, we provide updated data and our experience on the incidence of various IEM and endocrine disorders among the Saudi population, highlight the role of false positive results of biotinidase activity that can increase the recall rate and lead to overestimation of the incidence data, and recommend multicenter studies to achieve a successful national NBS program. |
